BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38426242)

  • 21. Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis.
    Kroese TE; van Laarhoven HWM; Nilsson M; Lordick F; Guckenberger M; Ruurda JP; D'Ugo D; Haustermans K; van Cutsem E; van Hillegersberg R; van Rossum PSN
    Eur J Cancer; 2022 May; 166():254-269. PubMed ID: 35339868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer.
    Rogowski P; Trapp C; von Bestenbostel R; Schmidt-Hegemann NS; Shi R; Ilhan H; Kretschmer A; Stief C; Ganswindt U; Belka C; Li M
    Radiat Oncol; 2021 Jun; 16(1):125. PubMed ID: 34193194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review.
    Abufaraj M; Dalbagni G; Daneshmand S; Horenblas S; Kamat AM; Kanzaki R; Zlotta AR; Shariat SF
    Eur Urol; 2018 Apr; 73(4):543-557. PubMed ID: 29122377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncological and perioperative outcomes of surgery with or without metastasis-directed therapy as part of a multimodal treatment in men with de-novo oligometastatic prostate cancer.
    Pellegrino A; Gandaglia G; de Angelis M; Fallara G; Mazzone E; Stabile A; Pellegrino F; Robesti D; Leni R; Scuderi S; Cucchiara V; Cirulli GO; Barletta F; Montorsi F; Briganti A
    World J Urol; 2023 Aug; 41(8):2069-2076. PubMed ID: 37326656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapy.
    Wenzel M; Garcia CC; Hoeh B; Jorias C; Humke C; Koll F; Tselis N; Rödel C; Graefen M; Tilki D; Chun FKH; Mandel P
    Prostate; 2023 Oct; 83(14):1365-1372. PubMed ID: 37464963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiotherapy for the treatment of distant nodes metastases from oligometastatic urothelial cancer: A retrospective case series.
    Leonetti A; D'Abbiero N; Baldari G; Andreani S; Ruffini L; Viansone AA; Buti S
    Int J Urol; 2018 Oct; 25(10):879-886. PubMed ID: 30103254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.
    Steuber T; Jilg C; Tennstedt P; De Bruycker A; Tilki D; Decaestecker K; Zilli T; Jereczek-Fossa BA; Wetterauer U; Grosu AL; Schultze-Seemann W; Heinzer H; Graefen M; Morlacco A; Karnes RJ; Ost P
    Eur Urol Focus; 2019 Nov; 5(6):1007-1013. PubMed ID: 29530632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Local Therapies in Oligometastatic and Oligoprogressive Prostate Cancer.
    Deek MP; Phillips RM; Tran PT
    Semin Radiat Oncol; 2021 Jul; 31(3):242-249. PubMed ID: 34090651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of Clinically Regional Node-Positive Urothelial Carcinoma of the Bladder.
    Reitblat C; Bellmunt J; Gershman B
    Curr Oncol Rep; 2021 Feb; 23(2):24. PubMed ID: 33559760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distant metastasis without regional progression in non-muscle invasive bladder cancer: case report and pooled analysis of literature.
    Xu T; Gu W; Wang X; Xia L; He Y; Dong F; Yang B; Yao X
    World J Surg Oncol; 2022 Jul; 20(1):226. PubMed ID: 35794571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Local and metastatic curative radiotherapy in patients with de novo oligometastatic prostate cancer.
    Reverberi C; Massaro M; Osti MF; Anzellini D; Marinelli L; Montalto A; De Sanctis V; Valeriani M
    Sci Rep; 2020 Oct; 10(1):17471. PubMed ID: 33060732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metastasis-Directed Therapy for Oligometastatic Castration-Sensitive Prostate Cancer: An Alternative to ADT?
    Cahill EM; Pfail JL; Fu MZ; Saraiya B; Mayer T; Stephenson RD; Ennis RD; Hathout L; Deek MP; Ghodoussipour S; Jang TL
    Curr Urol Rep; 2023 Jul; 24(7):299-306. PubMed ID: 37017928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stereotactic radiotherapy in oligometastatic cancer.
    Kennedy TAC; Corkum MT; Louie AV
    Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S16. PubMed ID: 28917254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms.
    No HJ; Raja N; Von Eyben R; Das M; Roy M; Myall N; Neal J; Wakelee H; Chin A; Diehn M; Loo BW; Chang DT; Pollom EL; Vitzthum LK
    Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):603-610. PubMed ID: 35654305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term Outcomes of a Phase 2 Trial of Chemotherapy With Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer.
    Petty WJ; Urbanic JJ; Ahmed T; Hughes R; Levine B; Rusthoven K; Papagikos M; Ruiz JR; Lally BE; Chan M; Clark H; D'Agostino RB; Blackstock AW
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):527-535. PubMed ID: 30003996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus.
    Zilli T; Achard V; Dal Pra A; Schmidt-Hegemann N; Jereczek-Fossa BA; Lancia A; Ingrosso G; Alongi F; Aluwini S; Arcangeli S; Blanchard P; Conde Moreno A; Couñago F; Créhange G; Dirix P; Gomez Iturriaga A; Guckenberger M; Pasquier D; Sargos P; Scorsetti M; Supiot S; Tree AC; Zapatero A; Le Guevelou J; Ost P; Belka C
    Radiother Oncol; 2022 Nov; 176():199-207. PubMed ID: 36228761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document.
    Lievens Y; Guckenberger M; Gomez D; Hoyer M; Iyengar P; Kindts I; Méndez Romero A; Nevens D; Palma D; Park C; Ricardi U; Scorsetti M; Yu J; Woodward WA
    Radiother Oncol; 2020 Jul; 148():157-166. PubMed ID: 32388150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.
    De Bruycker A; Spiessens A; Dirix P; Koutsouvelis N; Semac I; Liefhooghe N; Gomez-Iturriaga A; Everaerts W; Otte F; Papachristofilou A; Scorsetti M; Shelan M; Siva S; Ameye F; Guckenberger M; Heikkilä R; Putora PM; Zapatero A; Conde-Moreno A; Couñago F; Vanhoutte F; Goetghebeur E; Reynders D; Zilli T; Ost P
    BMC Cancer; 2020 May; 20(1):406. PubMed ID: 32398040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study.
    Arrieta O; Barrón F; Maldonado F; Cabrera L; Corona-Cruz JF; Blake M; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; García O; Arén O; De la Garza J
    Lung Cancer; 2019 Apr; 130():67-75. PubMed ID: 30885354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.